- Age of Menarche in a Longitudinal US Cohort. Journal of Pediatric and Adolescent Gynecology. 2018; 31(4):339-345. .
- This study incorporated reports about menarche using both the participant as well as their mother/guardian in a longitudinal, multisite study. Median age of menarche in participants was 12.25 years and was influenced by body mass index as well as race/ethnicity. Earlier pubertal maturation was associated with a slower tempo through puberty, potentially extending this critical window of susceptibility.
- Performance of the Atlas Genetics Rapid Test for Chlamydia trachomatis and Womens Attitudes Toward Point-Of-Care Testing. Sexually Transmitted Diseases. 2018; 45(11):723-727. .
- Performance of a novel, rapid, point-of-care diagnostic test for Chlamydia trachomatis was assessed, with testing among 296 adolescent and adult women showing that this 30-minute test resulted in high sensitivity and specificity. Most women preferred the easy collection method and were willing to wait in the doctor's office for results to obtain treatment.
- Faculty Members Self-Awareness, Leadership Confidence, and Leadership Skills Improve after an Evidence-Based Leadership Training Program. The Journal of Pediatrics. 2018; 199:4-6.e2. .
- This study examines the impact of a leadership development program for mid-level faculty. Results indicated that the program significantly improved participants’ confidence; self-awareness; and strategic, operational, and relational skills. The analysis of qualitative data demonstrated the positive impact of the Core Leadership Program on the development of participants’ supportive social networks, improved communication capabilities, and increased engagement.
- Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction. Journal of Adolescent Health. 2018; 63(1):43-49. .
- This study demonstrates that anogenital HPV prevalence was high and vaccination rates were low among young men (13-26 years old) two to four years after vaccine introduction, underscoring the urgency of increasing vaccination rates and vaccinating prior to sexual initiation.
- Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics. 2019; 143(2). .
- Human papillomavirus (HPV) prevalence was determined between 2006 (before HPV vaccine introduction) and 2017 (11 years after HPV vaccine introduction) in Cincinnati, Ohio. Among vaccinated women, vaccine-type HPV detection decreased 81% (demonstrating vaccine effectiveness), and among unvaccinated women, vaccine-type HPV decreased 40% (demonstrating herd protection). In this first study of the real-world effectiveness of human papillomavirus (HPV) vaccination more than 10 years after vaccine introduction, estimated vaccine effectiveness was 80.1%.